#tirzepatide
Eli Lilly becomes first health-care firm to briefly reach $1 trillion market value
Eli Lilly reached a historic milestone on Friday when it briefly surpassed a $1 trillion market capitalization, becoming the first health-care company in the world to enter a territory long dominated by technology giants. The company’s stock hovered near $1,048 per share during morning trading, touching the trillion-dollar threshold before pulling back slightly. It is only the second nontechnology business in the United States to reach this valuation, following Berkshire Hathaway’s climb
Eli Lilly becomes first health-care firm to briefly reach $1 trillion market value
Eli Lilly reached a historic milestone on Friday when it briefly surpassed a $1 trillion market capitalization, becoming the first health-care company in the world to enter a territory long dominated by technology giants. The company’s stock hovered near $1,048 per share during morning trading, touching the trillion-dollar threshold before pulling back slightly. It is only the second nontechnology business in the United States to reach this valuation, following Berkshire Hathaway’s climb
New Study Links Weight-Loss Drugs to Serious Eye Conditions and Vision Loss
Weight-loss drugs, particularly GLP-1 medications like semaglutide and tirzepatide, are gaining traction among diabetes and obesity patients in India. While these drugs offer benefits like controlling blood sugar and aiding in weight loss, recent studies have uncovered potential eye health risks. A new study published in JAMA has linked these medications to rare but serious eye conditions, with a focus on optic nerve disorders such as non-arteritic anterior is
New Study Links Weight-Loss Drugs to Serious Eye Conditions and Vision Loss
Weight-loss drugs, particularly GLP-1 medications like semaglutide and tirzepatide, are gaining traction among diabetes and obesity patients in India. While these drugs offer benefits like controlling blood sugar and aiding in weight loss, recent studies have uncovered potential eye health risks. A new study published in JAMA has linked these medications to rare but serious eye conditions, with a focus on optic nerve disorders such as non-arteritic anterior is









